Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
High psychological dependence potential with risk increasing with dose and duration of treatment. Risk factors include dependent personality, use of short-acting and high-potency benzodiazepines, and history of substance abuse.
Physical dependence occurs in approximately one-third of individuals treated with benzodiazepines for longer than 4 weeks. Midazolam infusions may induce tolerance and withdrawal syndrome in a matter of days. Sudden discontinuation can be dangerous or life-threatening, with withdrawal symptoms ranging from insomnia and anxiety to seizures and psychosis. Gradual tapering is essential to minimize withdrawal and rebound effects.
Benzodiazepine overdose in healthy individuals is rarely life-threatening with proper medical support. Toxicity increases significantly when combined with other CNS depressants, in the elderly, those with obstructive pulmonary disease, or when administered intravenously. Serious cardiorespiratory adverse reactions have occurred, sometimes resulting in death or permanent neurologic effects.
| Species | Route | Value |
|---|---|---|
| rat | oral | 215 mg/kg |
Long-term use of benzodiazepines has been associated with long-lasting deficits in memory, showing only partial recovery six months after cessation; it remains unclear whether full recovery occurs after longer periods of abstinence.
Respiratory depression is a known effect at typical doses, with serious respiratory adverse reactions including hypoventilation, airway obstruction, and apnea reported primarily at higher doses, in combination with other CNS depressants, or in vulnerable populations.
Hypotension due to reduction in systemic vascular resistance and increased heart rate can occur, particularly with rapid intravenous administration; serious cardiac adverse reactions have been reported in clinical settings.
Psychosis may occur as a withdrawal symptom, particularly with abrupt discontinuation after prolonged use. Paradoxical reactions including anxiety, aggressive or violent behavior, and uncontrollable emotional responses can occur in rare susceptible individuals, particularly in children, elderly, those with history of alcohol use or aggressive behavior, and with intravenous administration.
While midazolam itself has anticonvulsant properties, withdrawal from benzodiazepines can cause seizures that may be life-threatening. Paradoxical worsening of seizures occasionally occurs, and some benzodiazepines may trigger seizures in individuals with epilepsy. Gradual dose reduction is essential to prevent withdrawal seizures in dependent individuals.
Midazolam was synthesized in 1975 by Walser and Fryer at Hoffmann-LaRoche, Inc. in the United States. The compound was patented in 1974 and came into medical use in 1982. Its water solubility distinguished it from earlier benzodiazepines, as this property made it significantly less likely to cause…
Available only with a valid medical prescription. Subject to pharmaceutical dispensing regulations requiring prescriber authorization.
Controlled under the Controlled Substances Act as a Schedule IV substance, indicating low potential for abuse and low risk of dependence relative to Schedule III substances. DEA registration number 2884. First approved by the FDA in 1985 and remains available by prescription for various medical indications including procedural sedation, anesthesia induction, and seizure treatment.
Regulated as a prescription-only medication. Dispensing requires valid medical authorization from a licensed prescriber.
9 sources cited